Side effect profile and its correlation with genetic mutation among stomach and intestinal cancer patients who are receiving chemotherapy
Not Applicable
- Conditions
- Health Condition 1: C15-C26- Malignant neoplasms of digestive organs
- Registration Number
- CTRI/2024/05/067630
- Lead Sponsor
- KMC MANIPA
- Brief Summary
Not available
- Detailed Description
Not available
Recruitment & Eligibility
- Status
- Open to Recruitment
- Sex
- Not specified
- Target Recruitment
- 0
Inclusion Criteria
1)Patients aged more than 18 years and older
2)Patients with GI malignancy receiving fluoropyrimidines based chemotherapy
Exclusion Criteria
1) Patients with age less than 18years
2)Patient not consenting for DPYD testing
Study & Design
- Study Type
- Observational
- Study Design
- Not specified
- Primary Outcome Measures
Name Time Method To correlate DPYD (Dihydropyrimidine Dehydrogenase) gene mutation and toxicity <br/ ><br>profile among patients receiving fluoropyrimidines based chemotherapy.Timepoint: DPYD mutation testing - at baseline, before starting chemotherapy
- Secondary Outcome Measures
Name Time Method Prevalence of DPYD gene mutation & its allelic variants among patients receiving <br/ ><br>fluoropyrimidines based chemotherapy <br/ ><br> <br/ ><br>Association of DPYD genotype with toxicity profile among patients receiving <br/ ><br>fluoropyrimidines based chemotherapyTimepoint: toxicity profile will be documented at 4 weeks , 8 weeks & 24 weeks